Modification of cerebral vasoconstriction with hyperventilation in normal man by thymoxamine.
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000328:Adult; D001794:Blood Pressure; D001921:Brain / Q000098:blood supply*; D002245:Carbon Dioxide / Q000378:metabolism; D002560:Cerebrovascular Circulation; D003250:Constriction / Q000187:drug effects; D006339:Heart Rate; D006801:Humans; D006985:Hyperventilation / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D013948:Moxisylyte / Q000494:pharmacology; D010313:Partial Pressure; D011868:Radioisotopes; D012146:Rest; D013565:Sympatholytics / Q000494:pharmacology*; D013729:Terpenes / Q000494:pharmacology*; D014666:Vasomotor System / Q000187:drug effects*; D014692:Ventilation-Perfusion Ratio / Q000187:drug effects; D014978:Xenon
D000317:Adrenergic alpha-Antagonists; D011868:Radioisotopes; D013565:Sympatholytics; D013729:Terpenes; D002245:Carbon Dioxide; D014978:Xenon; D013948:Moxisylyte